Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sarepta licenses, options Duchenne's gene therapy programs from Nationwide Children's; later exercised

Executive Summary

Sarepta Therapeutics Inc. signed concurrent agreements to research and develop two preclinical Duchenne muscular dystrophy (DMD) gene therapy candidates in collaboration with Nationwide Children's Hospital, exclusively licensing the institution's Galgt2 (beta1, 4-N- acetylgalactosamine galactosyltransferase) program and also securing an exclusive option for Nationwide's microdystrophin program.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies